|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
1,250,000,000 |
Market
Cap: |
80.88(B) |
Last
Volume: |
7,412,694 |
Avg
Vol: |
8,704,124 |
52
Week Range: |
$63.43 - $87.29 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 259 |
Guru Rank Value : 4.6 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
2,000 |
25,472 |
38,458 |
80,792 |
Total Sell Value |
$145,920 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
Total People Sold |
1 |
3 |
3 |
4 |
Total Sell Transactions |
1 |
5 |
9 |
14 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Martin John C |
Executive Chairman |
|
2018-02-01 |
4 |
OE |
$23.60 |
$1,180,000 |
D/D |
50,000 |
3,046,766 |
|
- |
|
Alton Gregg H |
EVP,Corporate &Medical Affairs |
|
2018-02-01 |
4 |
AS |
$83.29 |
$2,087,860 |
D/D |
(25,000) |
37,738 |
|
- |
|
Alton Gregg H |
EVP,Corporate &Medical Affairs |
|
2018-02-01 |
4 |
OE |
$40.56 |
$699,660 |
D/D |
17,250 |
62,738 |
|
- |
|
Young Kevin |
Chief Operating Officer |
|
2018-02-01 |
4 |
D |
$83.49 |
$18,201 |
D/D |
(218) |
15,329 |
|
- |
|
Young Kevin |
Chief Operating Officer |
|
2018-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
620 |
15,547 |
|
- |
|
Young Kevin |
Chief Operating Officer |
|
2018-01-31 |
4 |
D |
$83.80 |
$189,304 |
D/D |
(2,259) |
14,927 |
|
- |
|
Young Kevin |
Chief Operating Officer |
|
2018-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
7,110 |
17,186 |
|
- |
|
Meyers James R |
EVP Worldwide Commercial Ops |
|
2018-01-16 |
4 |
AS |
$80.00 |
$8,024,364 |
D/D |
(100,000) |
2,715 |
|
- |
|
Meyers James R |
EVP Worldwide Commercial Ops |
|
2018-01-16 |
4 |
OE |
$21.58 |
$2,157,500 |
D/D |
100,000 |
102,715 |
|
- |
|
Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
|
2018-01-11 |
4 |
AS |
$79.00 |
$2,370,000 |
D/D |
(30,000) |
45,488 |
|
- |
|
Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
|
2018-01-11 |
4 |
OE |
$24.91 |
$932,062 |
D/D |
25,875 |
75,488 |
|
- |
|
Martin John C |
Executive Chairman |
|
2018-01-02 |
4 |
AS |
$72.26 |
$3,681,235 |
D/D |
(50,000) |
2,996,766 |
|
- |
|
Martin John C |
Executive Chairman |
|
2018-01-02 |
4 |
OE |
$23.60 |
$1,180,000 |
D/D |
50,000 |
3,046,766 |
|
- |
|
Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
|
2018-01-02 |
4 |
AS |
$72.34 |
$1,108,019 |
D/D |
(15,000) |
49,613 |
|
- |
|
Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
|
2018-01-02 |
4 |
OE |
$24.91 |
$214,806 |
D/D |
8,625 |
64,613 |
|
- |
|
Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
|
2017-12-01 |
4 |
AS |
$74.46 |
$1,119,552 |
D/D |
(15,000) |
55,988 |
|
- |
|
Alton Gregg H |
EVP Comm&Acs ALA, Corp&Med Aff |
|
2017-12-01 |
4 |
OE |
$24.91 |
$214,806 |
D/D |
8,625 |
70,988 |
|
- |
|
Martin John C |
Executive Chairman |
|
2017-12-01 |
4 |
AS |
$74.35 |
$5,498,385 |
D/D |
(73,333) |
2,996,766 |
|
- |
|
Martin John C |
Executive Chairman |
|
2017-12-01 |
4 |
OE |
$21.58 |
$1,582,159 |
D/D |
73,333 |
3,070,099 |
|
- |
|
Bischofberger Norbert W |
EVP, R&D and CSO |
|
2017-11-20 |
4 |
GD |
$0.00 |
$0 |
I/I |
10,000 |
2,308,407 |
|
- |
|
Milligan John F |
President and CEO |
|
2017-11-13 |
4 |
AS |
$72.88 |
$16,034,678 |
D/D |
(220,000) |
1,165,924 |
|
- |
|
Milligan John F |
President and CEO |
|
2017-11-13 |
4 |
OE |
$21.58 |
$4,746,500 |
D/D |
220,000 |
1,385,924 |
|
- |
|
Meyers James R |
EVP Worldwide Commercial Ops |
|
2017-11-09 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,327 |
129,760 |
|
- |
|
Meyers James R |
EVP Worldwide Commercial Ops |
|
2017-11-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,327 |
2,715 |
|
- |
|
Meyers James R |
EVP Worldwide Commercial Ops |
|
2017-11-09 |
4 |
D |
$73.02 |
$100,256 |
D/D |
(1,373) |
4,042 |
|
- |
|
2499 Records found
|
|
Page 22 of 100 |
|
|